Innova Vascular completes enrollment in TRUST pulmonary embolism study

Innova Vascular said it has finished enrolling patients in its TRUST IDE study of the Laguna Thrombectomy System for pulmonary embolism, a milestone in the company’s effort to generate clinical evidence for its endovascular clot-removal platform. The company plans to share study findings at the VIVA Conference in Las Vegas on Oct. 5, 2026.

Why it matters: - Pulmonary embolism can quickly strain the cardiovascular system and may require rapid intervention. - Innova Vascular’s TRUST study is testing whether the Laguna Thrombectomy System can safely and effectively remove clot from the pulmonary vasculature. - The study completion advances a pivotal clinical program that could support broader physician use of the system if results are favorable.

What happened: - Innova Vascular announced completion of patient enrollment in the TRUST pivotal Investigational Device Exemption clinical study. - The study evaluates the Laguna Thrombectomy System for treatment of pulmonary embolism. - TRUST enrolled 107 patients across 17 clinical sites. - The company said it expects to complete analysis of the study and present findings at the VIVA Conference in Las Vegas on Oct. 5, 2026.

The details: - The Laguna Thrombectomy System combines aspiration and mechanical clot-retrieval technologies. - The system includes the Malibu Aspiration Catheter System and the Laguna Clot Retriever System. - The Malibu system offers intermediate- and large-bore aspiration catheter options in 12Fr, 16Fr, 20Fr, and 24Fr outer diameters. - The Laguna Clot Retriever System is designed to mechanically delaminate, engage and retrieve thrombus. - The Laguna Clot Retriever System may be used with the Malibu Aspiration Catheter System at the physician’s discretion. - Dr. S. Jay Mathews, global co-principal investigator of the TRUST study, said deep catheter delivery into the pulmonary vasculature is important for performing thrombectomy in patients with pulmonary embolism. - Dr. Mahmood Razavi said the choice between intermediate-bore and large-bore aspiration catheters gives physicians flexibility to tailor treatment to vessel anatomy, clot burden, morphology and location. - Dr. Raj Khalsa said the study enrollment milestone reflects progress for Innova Vascular and the TRUST clinical program. - Innova Vascular describes the Laguna Thrombectomy System as a complementary technology set for thrombus removal.

Between the lines: - The enrollment milestone suggests the company is moving from trial recruitment toward data generation and potential regulatory and clinical-readout steps. - The repeated focus on catheter size, navigability and clot interaction signals that device design and procedural flexibility are central to the product story. - The VIVA Conference presentation could become the key near-term catalyst for investors and clinicians watching the program.

What's next: - Innova Vascular plans to finish its analysis of the TRUST study. - The company expects to share the findings with the medical community at VIVA in Las Vegas on Oct. 5, 2026. - Further progress will depend on the study results and how clinicians interpret the system’s safety and effectiveness profile.

The bottom line: - Innova Vascular has moved its Laguna thrombectomy platform one step closer to a potential clinical and commercial inflection point by completing enrollment in its pivotal pulmonary embolism study.